Compare Stocks: BNTC, AAPG, KARD, and ORIC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$15.36 -3.4%	$17.03	$14.55 ▼ $40.23	$1.44B	0.12	5,972 shs	8,994 shs
BNTC Benitec Biopharma	$8.98 -6.3%	$11.96	$8.92 ▼ $16.76	$313.25M	0.25	154,743 shs	135,137 shs
KARD Kardigan	$14.79 +3.8%	$19.21	$13.75 ▼ $27.00	$1.38B	N/A	859,691 shs	524,433 shs
ORIC Oric Pharmaceuticals	$12.20 -2.6%	$12.98	$7.23 ▼ $14.93	$1.27B	0.99	1.48 million shs	1.23 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	0.00%	+3.36%	-12.86%	-16.97%	-61.19%
BNTC Benitec Biopharma	0.00%	-6.36%	-27.81%	-32.07%	-35.90%
KARD Kardigan	0.00%	0.00%	-28.69%	-39.26%	+1,478,999,900.00%
ORIC Oric Pharmaceuticals	0.00%	-7.29%	-4.24%	+4.81%	+4.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$15.36 -3.4%	$17.03	$14.55 ▼ $40.23	$1.44B	0.12	5,972 shs	8,994 shs
BNTC Benitec Biopharma	$8.98 -6.3%	$11.96	$8.92 ▼ $16.76	$313.25M	0.25	154,743 shs	135,137 shs
KARD Kardigan	$14.79 +3.8%	$19.21	$13.75 ▼ $27.00	$1.38B	N/A	859,691 shs	524,433 shs
ORIC Oric Pharmaceuticals	$12.20 -2.6%	$12.98	$7.23 ▼ $14.93	$1.27B	0.99	1.48 million shs	1.23 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	0.00%	+3.36%	-12.86%	-16.97%	-61.19%
BNTC Benitec Biopharma	0.00%	-6.36%	-27.81%	-32.07%	-35.90%
KARD Kardigan	0.00%	0.00%	-28.69%	-39.26%	+1,478,999,900.00%
ORIC Oric Pharmaceuticals	0.00%	-7.29%	-4.24%	+4.81%	+4.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.20	Buy	$46.43	202.27% Upside
BNTC Benitec Biopharma	2.60	Moderate Buy	$24.00	167.26% Upside
KARD Kardigan	2.50	Moderate Buy	$42.25	185.67% Upside
ORIC Oric Pharmaceuticals	2.80	Moderate Buy	$20.18	65.42% Upside

Current Analyst Ratings Breakdown

Latest BNTC, AAPG, KARD, and ORIC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/23/2026	ORIC Oric Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$26.00
9/15/2026	BNTC Benitec Biopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/15/2026	BNTC Benitec Biopharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform
9/15/2026	BNTC Benitec Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$16.00 ➝ $17.00
9/14/2026	KARD Kardigan	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/25/2026	KARD Kardigan	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $46.00
8/21/2026	AAPG Ascentage Pharma Group International	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$48.00
8/10/2026	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $27.00
7/28/2026	BNTC Benitec Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$16.00
7/28/2026	BNTC Benitec Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$16.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$82.10M	17.47	N/A	N/A	$2.04 per share	7.53
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	$5.15 per share	N/A
KARD Kardigan	N/A	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$177.71M	N/A	N/A	768.00	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	-$45.55M	-$0.98	N/A	N/A	N/A	N/A	-28.41%	-27.76%	11/13/2026 (Estimated)
KARD Kardigan	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	-$129.47M	-$1.35	N/A	N/A	N/A	N/A	-35.35%	-33.39%	11/12/2026 (Estimated)

Latest BNTC, AAPG, KARD, and ORIC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/14/2026	Q4 2026	BNTC Benitec Biopharma	-$0.2643	-$0.26	+$0.0043	-$0.2590	$13.70 million	N/A
8/19/2026	H1 2026	AAPG Ascentage Pharma Group International	N/A	-$0.65	N/A	-$0.6450	N/A	$22.24 million
8/11/2026	Q2 2026	KARD Kardigan	N/A	-$4.61	N/A	-$4.61	N/A	N/A
8/3/2026	Q2 2026	ORIC Oric Pharmaceuticals	-$0.3594	-$0.38	-$0.0207	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
KARD Kardigan	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	1.09	1.22	1.18
BNTC Benitec Biopharma	N/A	34.00	34.00
KARD Kardigan	N/A	8.72	N/A
ORIC Oric Pharmaceuticals	N/A	13.19	13.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
BNTC Benitec Biopharma	52.19%
KARD Kardigan	N/A
ORIC Oric Pharmaceuticals	95.05%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
BNTC Benitec Biopharma	4.80%
KARD Kardigan	N/A
ORIC Oric Pharmaceuticals	5.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	767	93.40 million	N/A	N/A
BNTC Benitec Biopharma	24	34.88 million	33.21 million	No Data
KARD Kardigan	241	93.50 million	N/A	N/A
ORIC Oric Pharmaceuticals	111	103.65 million	97.75 million	Optionable

BNTC, AAPG, KARD, and ORIC Headlines

Recent News About These Companies

Oric Pharmaceuticals Director Richard Heyman Files Form 144 to Sell 8,100 Shares

October 3 at 7:42 PM | kalkinemedia.comK

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

October 2 at 4:30 PM | globenewswire.com

Oric Pharmaceuticals (NASDAQ:ORIC) Stock: Insider Dominic Piscitelli Sells 13,400 Shares

October 1 at 4:23 AM | americanbankingnews.com

Oric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 13,400 Shares of Company Stock

September 30, 2026 | insidertrades.com

Oric Pharmaceuticals (NASDAQ:ORIC) CFO Sells $181,302.00 in Stock

September 29, 2026 | marketbeat.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

September 29, 2026 | americanbankingnews.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Has Average Target Price of $20.18

September 29, 2026 | marketbeat.com

1,078,055 Shares of Oric Pharmaceuticals, Inc. $ORIC Purchased by Bank of America Corp DE

September 26, 2026 | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Time to Buy?

September 25, 2026 | americanbankingnews.com

BTIG Research Initiates Coverage on Oric Pharmaceuticals (NASDAQ:ORIC)

September 25, 2026 | americanbankingnews.com

BTIG initiates coverage of ORIC Pharmaceuticals at buy

September 24, 2026 | msn.com

ORIC Pharmaceuticals stock trades 10.7 percent below its 52-week high

September 24, 2026 | ad-hoc-news.deA

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Still a Buy?

September 23, 2026 | marketbeat.com

BTIG Initiates ORIC Pharmaceuticals at Buy With $26 Price Target

September 23, 2026 | marketscreener.comM

Oric Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated at BTIG Research

September 23, 2026 | marketbeat.com

Why ORIC Pharmaceuticals, Inc.’s (ORIC) Stock Is Up 5.02%

September 17, 2026 | aaii.comA

ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16, 2026 | seekingalpha.com

ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch

September 15, 2026 | insidermonkey.com

WINTON GROUP Ltd Buys Shares of 83,000 Oric Pharmaceuticals, Inc. $ORIC

September 15, 2026 | marketbeat.com

Squarepoint Ops LLC Purchases Shares of 344,343 Oric Pharmaceuticals, Inc. $ORIC

September 13, 2026 | marketbeat.com

Bank of New York Mellon Corp Takes Position in Oric Pharmaceuticals, Inc. $ORIC

September 8, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BNTC, AAPG, KARD, and ORIC Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$15.36 -0.54 (-3.40%)

Closing price 10/2/2026 03:47 PM Eastern

Extended Trading

$15.07 -0.29 (-1.89%)

As of 10/2/2026 07:30 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Benitec Biopharma NASDAQ:BNTC

$8.98 -0.60 (-6.26%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$8.99 +0.01 (+0.11%)

As of 10/2/2026 07:34 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Kardigan NASDAQ:KARD

$14.79 +0.54 (+3.79%)

As of 10/2/2026 04:00 PM Eastern

Kardigan Inc. is a clinical-stage precision therapeutics company developing medicines which target the root cause of specific cardiovascular diseases. Kardigan Inc. is based in South San Francisco, California.

Oric Pharmaceuticals NASDAQ:ORIC

$12.20 -0.32 (-2.56%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$12.20 +0.01 (+0.04%)

As of 10/2/2026 07:30 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNTC, AAPG, KARD, and ORIC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNTC, AAPG, KARD, and ORIC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNTC, AAPG, KARD, and ORIC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BNTC, AAPG, KARD, and ORIC Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

Benitec Biopharma NASDAQ:BNTC

Kardigan NASDAQ:KARD

Oric Pharmaceuticals NASDAQ:ORIC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNTC, AAPG, KARD, and ORIC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNTC, AAPG, KARD, and ORIC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNTC, AAPG, KARD, and ORIC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BNTC, AAPG, KARD, and ORIC Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

Benitec Biopharma NASDAQ:BNTC

Kardigan NASDAQ:KARD

Oric Pharmaceuticals NASDAQ:ORIC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools